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Abstract
Background: Although B cell depletion with rituximab (RTX) is an effective treatment strategy in rheumatoid
arthritis (RA), one third of patients do not achieve remission or low disease activity (LDA). Thus, identifying patients
who will benefit from RTX is highly desirable. In the present study we investigated whether lymphocyte subsets
other than B cells are predictors of a clinical response to RTX treatment.
Methods: Patients with RA who were receiving RTX for the first time were included in an observatory registry.
Clinical assessments, complete blood count and flow cytometry of lymphocyte subsets were obtained at baseline
and at week 24 after RTX. Complete data were available for 44 patients. Logistic regression and receiver operating
characteristic curve analyses were computed to analyze the predictive value of lymphocyte subsets for European
League Against Rheumatism (EULAR) response and LDA (defined as disease activity score in 28 joints (DAS28) ≤3.2)
at week 24.
Results: EULAR responders had lower total lymphocyte counts (LC), T cells and CD4 + T cells at baseline. Although
these parameters were independent predictors of EULAR response they failed in determining who would reach
LDA. In contrast, LC >2910/μl or plasmablast frequency >2.85 % at baseline predicted a significantly higher DAS28
at week 24 after RTX and identified patients not achieving LDA at week 24 with sensitivity of 93.3 % and specificity
of 44.8 %.
Conclusions: A combination of LC and plasmablast frequency identifies patients with RA who will not benefit from
RTX with high probability.
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Background
With the introduction of biologic disease-modifying
anti-rheumatic drugs (DMARDs) (bDMRDs) the arma-
mentarium to fight rheumatoid arthritis (RA) has been
dramatically enlarged [1]. However, we are unable to
predict which of these therapies would be optimal for a
certain patient. For example, B cell depletion with the
chimeric monoclonal antibody rituximab (RTX) is an ef-
fective treatment strategy for RA. However, a consider-
able proportion of around 30 % of patients with RA
treated with RTX fail to respond, particularly after previ-
ous therapy with tumor necrosis factor (TNF)-α inhibi-
tors [2]. Identification of patients likely to respond to
RTX treatment would result in an optimized treatment
strategy reducing unnecessary socio-economic costs and
potential side effects. Currently available clinical and
laboratory parameters predicting the success of RTX
therapy include the presence of rheumatoid factor (RF)
and/or anti-citrullinated peptide antibodies (ACPA), and
the absence of current glucocorticoid therapy [3–5]. In
addition, high serum calprotectin has been associated
with good or moderate response to RTX [6]. Further-
more, several authors have demonstrated that patients
with RA who have a high frequency of plasmablasts are
less likely to respond to RTX [7–11].
All these factors, however, have been established to
predict EULAR response. Current recommendations
for the treatment of RA define remission or low disease
activity (LDA) in patients with long-standing disease as
the goal of treatment after 6 months [12], a target that
is not achieved with a moderate EULAR response in
many cases.
Whether factors other than B cell subsets or their
products might help us to find the optimal therapy for a
particular patient is still unknown. As several immune
competent cells are involved in the pathogenesis of RA
[13] the efficacy of a certain bDMARD might be deter-
mined not only by its defined target but also by cells
or molecules interacting with it. Thus, the influence
of RTX on T cells became an alternative focus of recent
investigations [14–16].
In the present study, we analyzed 1) whether baseline
levels of lymphocyte subsets other than those of B cells
may predict clinical response to RTX and 2) whether
changes in T cell subsets correlate with clinical outcomes.
Methods
Patients
Data from the Austrian Rituximab registry were used for
this study. The clinical protocol with a detailed descrip-
tion of inclusion and exclusion criteria, interventions,
and clinical and laboratory assessments has been described
earlier [11]. Briefly, consecutive patients were included
who fulfilled the 1987 American College of Rheumatology
(ACR) classification criteria for RA [17] and were receiving
RTX for the first time. All patients received 1000 mg RTX
preceded by the administration of 100 mg of prednisolone
at baseline and after 2 weeks. Complete blood count,
lymphocyte analysis, and assessment of disease activity
score in 28 joints (DAS28) using the erythrocyte sedimen-
tation rate were carried out before RTX treatment and at
week 24. Patients were classified according to European
League Against Rheumatism (EULAR) as good responders,
moderate responders, or non-responders [18]. LDA was
defined as a DAS28 ≤ 3.2 [19].
Lymphocyte analysis
Blood cell counts in peripheral blood samples were
obtained using a Beckman Coulter HMX hematology
analyzer (Beckman Coulter, Miami, FL, USA). For deter-
mination of lymphocyte subsets whole blood was stained
for CD45, CD3, CD19, CD4, CD8, CD56, and CD16 using
the BD Multitest IMK kit (Becton Dickinson, Heidelberg,
Germany). After fixation and erythrocyte lysis according to
the manufacturer’s protocol, cells were analyzed on a FACS
Calibur flow cytometer (Becton Dickinson) using FACS
Diva software (Becton Dickinson).
Statistical analysis
All statistical analyses were performed using the SPSS
program, version 21.0 (IBM, Chicago, IL, USA). Figures
were generated using GraphPad Prism 5 (La Jolla, CA,
USA). The Kolmogorov-Smirnov test was used to check
the normality of metric data. Two-group comparisons
were performed using the unpaired t test (parametric
data) or Mann-Whitney U test (non-parametric data).
For pairwise analysis of non-normally distributed data
we used Wilcoxon matched pairs test. Multiple compari-
sons were calculated using one-way analysis of variance
(ANOVA) (parametric data) or the Kruskal-Wallis test
(non-parametric data) and the appropriate post hoc tests
(the Bonferroni and Mann-Whitney U test, respectively).
We conducted inclusive logistic regression analyses
(maximum likelihood method) to investigate the associ-
ation between EULAR response or DAS28 ≤ 3.2 after
RTX treatment (dependent variable) and leucocyte count
(LC), B cell, T cell, CD4+T cell, CD8+T cell, and natural
killer (NK) cell count, and a combined LC and plasma-
blast score (predictors of primary interest) adjusting for
DAS28, current glucocorticoid therapy, disease duration,
sex, failure to respond to more than one TNF inhibitor
and ACPA status. To identify possible cutoffs for base-
line LC and plasmablast frequency distinguishing be-
tween EULAR responders and non-responders, receiving
operating characteristic (ROC) curves were constructed
by plotting sensitivity against one minus specificity vary-
ing the cutoffs and calculating the area under the curve
(AUC). Data are presented as mean ± standard error of
Stradner et al. Arthritis Research & Therapy  (2016) 18:190 Page 2 of 8
the mean unless indicated otherwise. Odds ratios (OR)




Because of technical problems, complete data on T and
B cell cytometry was available for only 44 of the 52
patients with RA who were receiving RTX. At week 24,
there were 33 patients (75.0 %) classified as EULAR re-
sponders and 15 patients (34.1 %) had achieved remis-
sion or LDA. Baseline characteristics are summarized in
Table 1. The baseline characteristics are representative
of a typical RA cohort with long-standing RA and high
disease activity.
Baseline lymphocyte counts predict EULAR response but
not LDA
We analyzed whether baseline levels of lymphocyte sub-
sets differed between responders and non-responders to
RTX therapy. Interestingly, baseline total lymphocyte
count (LC) was significantly higher in the non-responder
group compared to patients with EULAR response, as
depicted in Fig. 1a (2681 ± 360/μl and 1956 ± 124/μl, re-
spectively, P = 0.019). We found no significant difference
in baseline LC between patients with DAS28 > 3.2 and
DAS28 ≤ 3.2 at week 24.
Next we investigated if one or more of the lymphocyte
subsets were responsible for the negative correlation be-
tween EULAR response and cell count. We observed a
higher CD3+ T-cell count in non-responders than in
responders (2022 ± 904/μl, 1501 ± 110/μl, respectively,
P = 0.040, Fig. 1b). In addition, non-responders had
higher total numbers of B cells compared to responders
(421 ± 92/μl and 185 ± 18/μl, respectively, P = 0.001, Fig. 1c).
A detailed analysis of the B cell subsets in our cohort has
already been published [11]. Among the T-cell subsets
we found higher levels of CD4+T cells in the non-responder
group (1504 ± 205/μl and 1047 ± 84/μl, respectively, P =
0.19; Fig. 1d). Importantly, at baseline none of these popula-
tions was significantly different between patients with a
DAS28 > 3.2 or a DAS28 ≤ 3.2 at week 24. This was also
true for the plasmablast frequency, a predictor of EULAR
response identified previously [11]. Furthermore, we did
not detect any significant difference in the prevalence of
CD8+T cells and natural killer cells (data not shown). In
addition, DMARD therapy and glucocorticoid use had no
influence on lymphocyte counts or lymphocyte subsets
(Additional file 1: Table S1). In univariate logistic regression
analysis high baseline LC, B cell, T cell, and CD4+T cell
counts were negative predictors of EULAR response but
there were no predictors of LDA (Table 2).
Multivariate regression analysis as described in Methods
was then carried out to adjust the data for possible con-
founders, confirming the results from univariate analysis:
LC, T cell, B cell, and CD4+T cell counts were independent
negative predictors of EULAR response (Table 3).
Combining baseline LC and plasmablast frequency
predicts low disease activity
The current focus in RA therapy is to achieve remission
or LDA by 6 months [12]. None of the cellular biomarkers
evaluated so far solely predicted LDA. Therefore, we
investigated whether a combination of two biomarkers
could be used for predicting LDA. We hypothesized that
these biomarkers would have to identify a different patient
group each, in order to improve the prediction. By blot-
ting each of the candidate biomarkers against each other,
we found that high LC and high plasmablasts, a predictor
of EULAR response identified previously [11], each recog-
nized a different population of patients not reaching LDA
by week 24 (Fig. 2a). In contrast, all patients who did
reach LDA had low LC and low plasmablast frequency
(Fig. 2b). This finding prompted us to use a combination
of both biomarkers in inclusive disjunction. The cutoffs
for both values were chosen to yield at least 90 %
Table 1 Baseline characteristics of patients included in the study
Parameter Non-responders Responders P
value
DAS28 > 3.2 (week 24) DAS28≤ 3.2 (week 24) P
value(n = 11) (n = 33) (n = 29) (n = 15)
Age in years (mean ± SD) 58.9 ± 10.8 62.5 ± 13.3 0.423 61.8 ± 13.8 61.3 ± 10.7 0.898
Female gender, % 72 81 0.640 76 87 0.411
Disease duration in years (mean ± SD) 15.1 ± 12.7 12.9 ± 8.8 0.536 12.7 ± 10.5 15.4 ± 8.1 0.428
DAS28-ESR (mean ± SD) 5.0 ± 1.1 6.0 ± 1.1 0.008 5.8 ± 1.1 5.7 ± 1.3 0.753
RF-positive, % 100 87 0.236 86 100 0.138
ACPA-positive, % 78 76 0.909 72 85 0.399
Corticosteroids, % 36 30 0.061 34 26 0.608
Previous TNF inhibitors (mean ± SD) 1.7 ± 1.2 1.2 ± 0.9 0.194 1.5 ± 1.1 1.2 ± 0.7 0.346
Significant P values are indicated in bold numbers
DAS28 disease activity score in 28 joints, SD standard deviation, ESR erythrocyte sedimentation rate, RF rheumatoid factor IgM, ACPA anti-citrullinated peptide anti-
body, TNF tumor necrosis factor
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specificity for non-response generated by ROC analysis
(Additional file 2: Figure S1). Patients with elevated LC
>2910/μl or plasmablast frequency >2.85 % (hiLOP) at
baseline had a significantly higher DAS28 at week 24 after
treatment with RTX than patients who had LC and plas-
mablast frequency below the thresholds (loLAP) (DAS28
of 4.9 ± 0.3 and 3.7 ± 0.2, respectively; P = 0.002. Fig. 2c).
Positive and negative predictive values for achieving a
DAS28 ≤ 3.2 are given in Table 4.
To test if hiLOP was an independent predictor of a
DAS28 ≤ 3.2 we performed multivariate regression
corrected for possible confounders. Indeed, baseline hiLOP
significantly and independently predicted that patients
treated with RTX would not reach DAS28 ≤ 3.2 at week
24 (OR 0.11, 95 % CI 0.01–0.89, P = 0.037). In contrast,
other combinations of LC, plasmablast frequency, T cell,
B cell, or CD4+T cell counts were not predictive of a
DAS28 ≤ 3.2 in our analysis (data not shown).
T cell numbers are reduced after treatment with RTX but
do not correlate with clinical response
We also tested whether a change in the absolute T cell
count after therapy with RTX correlates with EULAR re-
sponse as reported previously [14, 20]. The absolute
number of T lymphocytes at week 24 after RTX was re-
duced to 79.9 % of baseline levels (1652 ± 113/μl to
Fig. 1 Rituximab (RTX) non-responders (NR) have higher baseline lymphocyte, T cell, and CD4+lymphocyte counts than responders (R). Lymphocyte
(a), CD45+CD3+ (b), CD45+CD19+ (c), and CD45+CD3+CD4+ (d) counts were obtained before treatment with RTX. European League Against
Rheumatism (EULAR) response and disease activity score in 28 joints (DAS28) were assessed at week 24 after treatment with RTX. Data are
presented as cells/μl. Each dot represents a patient; horizontal bars indicate the mean. Statistical significance was assessed using the Mann-Whitney U test.
*P <0.05, ***P <0.001
Table 2 Univariate logistic regression models predicting EULAR
response and DAS28 ≤ 3.2 at week 24 after rituximab
Baseline variables EULAR response DAS28≤ 3.2
OR (95 % CI) P value OR (95 % CI) P value
Leucocytesa 1.00 (1.00–1.00) 0. 926 1.00 (1.00–1.00) 0.892
LCa 0.91 (0.83–0.99) 0.030 0.97 (0.90–1.04) 0.420
Natural killer cellsa 0.93 (0.59–1.48) 0.766 0.85 (0.50–1.41) 0.524
B cellsa 0.48 (0.26–0.87) 0.015 0.79 (0.52–1.20) 0.274
T cellsa 0.90 (0.81–1.00) 0.050 0.98 (0.91–1.07) 0.692
CD4+ a 0.87 (0.76–0.99) 0.029 0.96 (0.86–1.08) 0.491
CD8+ a 0.94 (0.74–1.20) 0.607 1.061 (0.85–1.33) 0.640
aAbsolute values, multiplied by 100. EULAR European League Against
Rheumatism, DAS28 disease activity score in 28 joints, CI confidence interval,
LC total lymphocyte count, OR odds ratio (indicated per 100 cells/μl increase)
Significant P values are indicated in bold numbers
Table 3 Multivariate logistic regression models predicting




OR (95 % CI) P value
LCa 0.88 (0.80–0.89) 0.021
B cellsa 0.43 (0.22–0.88) 0.020
T cellsa 0.87 (0.70–0.96) 0.018
CD4+ a 0.82 (0.70–0.97) 0.015
aAbsolute values, multiplied by 100. EULAR European League Against
Rheumatism,CI confidence interval, LC total lymphocyte count, OR odds ratio
(indicated per 100 cells/μl increase)
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1320 ± 88/μl, P = 0.003, Fig. 3a). We also found a reduc-
tion of CD4+T lymphocytes (1174 ± 88/μl to 933 ± 60/μl,
P = 0.007, Fig. 3b), CD8+T lymphocytes (492 ± 44/μl to
399 ± 45/μl, P = 0.001) but not natural killer cell numbers
(242 ± 24/μl to 229 ± 24/μl, P = 0.475) by flow cytometry.
However, neither the reduction of T lymphocytes nor
the decrement of CD4+ T-cell levels was associated
with a EULAR response or a DAS28 ≤ 3.2 as outlined
in Fig. 3c and d (P > 0.05). Changes within the CD8+T
lymphocyte subset were also similar in responders and
non-responders (data not shown).
Discussion
Selection of a new DMARD for patients with RA who
are responding insufficiently to a current therapy is a
delicate decision. Currently the best predictor of reach-
ing remission or LDA is not an individual biomarker,
but the level of disease activity and its reduction, espe-
cially during the first 3 months of treatment [21].
Measurement of the LC is simple and cheap. In our
study 91 % of responders had LC below the cutoff of
<2910 lymphocytes/μl. Interestingly, this value is
higher than that reported by Ferraccioli et al. [3],
who found that a lymphocyte count below 1875/μl is
an excellent predictor of a good EULAR response fol-
lowing B cell depletion. The difference between cutoff
values may be related to differences in the two RA
cohorts: our patients had higher disease activity (5.8
versus 4.6), fewer of them took glucocorticoids (30 %
versus 80 %), and all were RF-IgM-positive (100 %
versus 85 %).
As LC characterized a different population of non-
responders compared to high levels of plasmablasts,
we combined the baseline values of LC and plasma-
blast frequency and generated an LOP score that has
high negative predictive value and sensitivity to iden-
tify patients who will not achieve low disease activity
under RTX. This is especially important for treatment
decisions in clinical practice, where the target of
treatment is remission or at least low disease activity
[12]. Our data suggest that LC and B cell subtyping
should be performed in patients before treatment de-
cisions. Treatment options other than RTX may be
preferred for patients who have hiLOP.
Fig. 2 Patients with high total lymphocyte counts (LC) or high frequency of plasmablasts (hiLOP) have higher disease activity. Baseline values of
LC and plasmablasts in patients not achieving low disease activity (LDA) after 24 weeks (a). Baseline values of LC and plasmablasts in patients
achieving LDA after 24 weeks (b). Dotted lines indicate the cutoff for baseline. Red and blue indicate the area for baseline hiLOP or low number of
total lymphocyte counts and plasmablasts (loLAP), respectively. Change in disease activity score in 28 joints (DAS28) in patients with baseline
loLAP and hiLOP (c). Statistical significance was assessed using the Mann-Whitney U test; ***P <0.001
Table 4 Contingency table of loLAP or hiLOP scores and
disease activity at week 24
loLAP hiLOP
DAS28≤ 3.2 14 1 Sensitivity: 93.3 %
DAS28 > 3.2 16 13 Specificity: 44.8 %
PPV: 46.7 % NPV: 92.9 %
hiLOP high number of total lymphocyte count or plasmablasts, loLAP low
number of total lymphocyte count and plasmablasts, DAS28 disease activity
score in 28 joints; PPV positive predictive value, NPV negative predictive value
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We observed a decrease in T cell numbers 24 weeks
after treatment with RTX. In line with our findings, in two
recent studies there was also a reduction in circulating T
cells in patients treated with RTX [14, 20]. Intriguingly,
the reduction in overall T cells after RTX in these studies
correlated with EULAR response, which we did not
confirm in our cohort. Again, differences in patient
characteristics may account for the divergent findings,
as more of our patients were RF-positive and fewer
were taking steroids.
How RTX might affect T cell homeostasis is still under
discussion. One possibility could be a direct effect on
CD20+ T cells. This has recently been demonstrated in
patients with multiple sclerosis [22], but it seems un-
likely in RA because of the small number of peripheral
T cells expressing this molecule as Melet et al. have indi-
cated [14]. Evidence for an indirect effect of RTX comes
from observations in lupus-prone MRL-lpr/lpr mice.
Analysis of B-cell-intact and B-cell-deficient mice dem-
onstrates that the expansion of activated and memory T
cells is highly dependent on the presence of B cells [23].
Furthermore, B cell depletion limits the generation of
CD4+ memory T cells and reduces protection against
disseminating virus infection [24]. Thus, diminishing the
number of B cells reduces signals for the activation and
expansion of T cells. In line with this are reports of a di-
minished number of activated CD69+ or CD154+ T cells
after successful B cell depletion therapy in humans with
systemic lupus erythematosus [25, 26].
How low numbers of total lymphocytes may be benefi-
cial for patients with RA treated with RTX is unknown.
Approximately 75 % of total lymphocytes are T cells and
60 % of these are CD4+ [27]. Within this population are
helper cells that are able to promote the survival of
autoreactive B cells [28]. Starting with a low number of
T lymphocytes the additional decrease in these cells
after RTX might be sufficient to disrupt the reciprocal
activation of auto-reactive T and B cells.
A limitation of our study is the small sample size and
the lack of detailed characterization of T cells. In addition,
as all our patients were RF-positive it was not possible to
meaningfully assess any statistical association between
autoantibodies and EULAR response. ACPA status, how-
ever, was neither linked with EULAR response nor con-
founded the predictive values of LC, CD4+T lymphocyte
count, or hiLOP outcome.
Fig. 3 T cell numbers are reduced after treatment with rituximab (RTX) but do not correlate with clinical response. CD45+CD3+ (a, c) and
CD45+CD3+CD4+ (b, d) lymphocytes of all patients were analyzed at the indicated time points after treatment with RTX (a, b) or at week 24,
separated according to European League Against Rheumatism (EULAR) response and disease activity in 28 joints (DAS28) at week 24 (c, d). Data are
presented as percentage change of the indicated lymphocyte subset compared to baseline (BL). Boxes represent the median, with 50 % of
cases within the boxes. Whiskers represent the minimum and maximum. Statistical significance was assessed using the Wilcoxon matched
pairs test (a, b) and one-way analysis of variance (c, d); *P <0.05, **P <0.01. R responders, NR non-responders
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Whether patients with high LC or plasmablast fre-
quency would benefit from an additional cycle of rituxi-
mab as suggested by Vital et al. [8] cannot be answered by
our study. As a first step we would like to confirm our
data in a prospective clinical trial selecting patients with
RA for RTX therapy according to their LOP score.
Conclusions
Currently, there are several bDMARDs available for the
treatment of RA, but despite a plethora of data from dif-
ferent studies no single biomarker has emerged that
might predict the response to different therapies. Here
we describe a combination of biomarkers, i.e., high LC
and plasmablast frequency at baseline, that reliably iden-
tify patients who are likely to fail to respond to RTX
treatment.
Additional files
Additional file 1: Table S1. One-way ANOVA for leucocyte subsets and
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Additional file 2: Figure S1. ROC curves of LC and CD4+lymphocyte
counts. Sensitivity for EULAR response blotted against false negative rate
(1-specificity), at various threshold settings for baseline LC and CD45+CD3
+CD4+ counts. The increasing area under the curve (AUC) corresponds to
higher diagnostic accuracy. (TIFF 42 kb)
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